BioSpace News Archive

Compass Therapeutics, a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the closing of a $60 million private placement financing and the completion of a reverse merger transaction with Olivia Ventures, Inc.

Approximately two-thirds of small businesses say that providing health insurance to their employees is now a higher priority as a result of COVID-19.

Exeltis USA, Inc, a division of Insud Pharma, today announced the launch of the updated slynd.com, the website for Slynd™ (drospirenone) tablets 4 mg, a novel estrogen-free oral contraceptive, in a physician and patient communication letter.

Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of antiviral therapies targeting chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, announced an expansion to their existing license agreement with Emory University (Emory) to include additional technology developed at Emory related to Aligos’ capsid assembly modulator (CAM) program in CHB

The following resolutions were passed at the Annual General Meeting of Hansa Biopharma AB on June 23, 2020

After a brain injury, cells that normally nourish nerves may actually kill them instead, a new study in rodents finds. This “reactive” phenomenon may be the driving factor behind neurodegenerative diseases like glaucoma, a leading cause of blindness.

The American Society of Hematology congratulates this year’s recipients of the Honorific Awards, the Society’s most prestigious awards which recognize hematologists who have made significant contributions to the field.

A new poll indicates that 59% of Canadians approve the use of psilocybin-mushrooms for terminally-ill patients.

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2020

Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering